Key Figures
The Metall Zug Group is committed to transparency, clarity and accuracy. Our key figures provide a comprehensive overview of the group's business development and our Business Units. Additional explanations of the key figures can be found in the published Annual Reports.
Net sales by Business Units 2025
in CHF million
194.6
Operating result (EBIT) 2025
in CHF million
-17.5
Employees (FTE) 2025
913
Net sales with third parties by region 2025
in %
Net sales by Business Units 2025
in %
Organic sales development 2025
in %
-0.8
Cash flow from operating activities 2025
in CHF million
-6.2
Earnings per share 2025
in CHF
-34.00
Equity ratio 2025
in %
67.4%
| Metall Zug Group | 2025 | 2024 | 1) | 2023 |
| 2022 | 2) | 2021 |
| |
|---|---|---|---|---|---|---|---|---|---|---|
in CHF million |
|
|
| |||||||
|
|
| ||||||||
| Performance |
|
|
| |||||||
| Net sales | 194.6 | 283.4 | 494.7 | 645.9 | 661.9 | |||||
| Trading operating result | -14.6 | 54.9 | 13.1 | 134.7 | 42.3 | |||||
| Result from strategic investments | -2.9 | 3.1 | 17.0 | 10.2 | 18.8 | |||||
| Operating result (EBIT) | -17.5 | 58.0 | 30.1 | 144.9 | 61.1 | |||||
| Net result | -16.7 | 52.8 | 26.1 | 136.1 | 53.3 | |||||
| Earnings per share (EPS) | -34.00 | 116.87 | 48.13 | 286.25 | 108.83 | |||||
|
|
|
| |||||||
| Sales development in % | -31.3 | -42.7 | -23.4 | -2.4 | -19.6 | |||||
| of which foreign currency impact in % | -1.6 | -0.8 | -2.5 | -0.3 | -0.1 | |||||
| of which acquisition & divestment impact in % | -29.0 | 3) | -33.6 | 3) | -25.7 | 4) | -11.6 | -30.0 | 5) | |
| Organic sales development in % | -0.8 | -8.3 | 4.8 | 9.5 | 10.5 | |||||
|
|
|
| |||||||
| Cash flow from operating activities | -6.2 | 2.8 | 9.5 | -6.0 | 48.9 | |||||
| in % of net sales | -3.2 | 1.0 | 1.9 | -0.9 | 7.4 | |||||
| Employees | 913 | 983 | 2’224 | 2’317 | 3’321 | |||||
| Personnel expenses | -101.7 | -154.7 | -218.8 | -282.3 | -303.0 | |||||
|
|
|
| |||||||
| Invested Capital |
|
|
| |||||||
| Total assets | 667.2 | 633.0 | 688.9 | 700.0 | 715.6 | |||||
|
|
|
| |||||||
| Net debt/net cash6) | -137.3 | -65.6 | -6.8 | 14.7 | 77.7 | |||||
| in % of total assets | -20.6 | -10.4 | -1.0 | 2.1 | 10.9 | |||||
|
|
|
| |||||||
| Current assets | 135.0 | 129.5 | 236.8 | 284.7 | 378.9 | |||||
| in % of total assets | 20.2 | 20.5 | 34.4 | 40.7 | 52.9 | |||||
|
|
|
| |||||||
| Fixed assets | 532.2 | 503.4 | 452.1 | 415.3 | 336.8 | |||||
| in % of total assets | 79.8 | 79.5 | 65.6 | 59.3 | 47.1 | |||||
|
|
|
| |||||||
| Strategic investments (associated companies) | 284.7 | 295.1 | 249.0 | 244.7 | 135.8 | |||||
| in % of total assets | 42.7 | 46.6 | 36.1 | 35.0 | 19.0 | |||||
|
|
|
| |||||||
| Shareholders' equity | 449.4 | 486.4 | 520.0 | 517.1 | 516.2 | |||||
| in % of total assets | 67.4 | 76.8 | 75.6 | 73.9 | 72.1 | |||||
|
|
|
| |||||||
| Investments in tangible and intangible assets | 45.5 | 33.9 | 36.2 | 34.8 | 34.7 | |||||
| Investments (expenses) in research and development | -26.1 | -33.2 | -41.0 | -54.6 | -60.4 |
1) On June 7, 2024, the Infection Control Business Unit and the Belimed Life Science Group were deconsolidated and contributed into |
2) On August 30, 2022, the Schleuniger Group (Wire Processing Business Unit) was deconsolidated and contributed into Komax Holding AG. In return, Metall Zug AG received a 25% stake in Komax Holding AG. As a consequence, the 2022 performance figures are not comparable with the other years stated. |
3) 2025 and 2024 solely in connection with the deconsolidation of the Infection Control Business Unit and the Belimed Life Science Group. |
4) Of which -24.6% related to the deconsolidation of the Schleuniger Group in 2023 (2022: -11.1%). |
5) Of which -31.7% related to the spin-off of V-ZUG Group in 2021. |
6) Net debt/net cash is made up of cash and cash equivalents and securities less financial liabilities. |
Net sales 2025
in CHF million
158.5
Operating result (EBIT) 2025
in CHF million / in % of net sales
-5.8 / 3.6%
Organic sales development 2025
in %
–2.6%
Employees (FTE) 2025
728
Net sales by segment 2025
in %
Net sales by region 2025
in %
| Medical Devices | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
in CHF million | |||||
| Net sales | 158.5 | 167.6 | 178.3 | 225.6 | 215.2 |
| Net sales development in % | -5.4 | -6.0 | -20.9 | 4.8 | 26.9 |
| - of which foreign currency impact in % | -2.7 | -1.1 | -2.8 | -0.6 | -0.3 |
| - of which acquisition & divestment impact in % | 0.0 | 0.0 | -4.0 | -3.2 | 2.5 |
| Organic net sales development in % | -2.6 | -4.9 | -14.1 | 8.6 | 24.7 |
| Net sales to third parties | 158.5 | 167.6 | 178.3 | 225.6 | 215.2 |
| - Switzerland | 7.8 | 10.1 | 9.4 | 8.1 | 8.2 |
| - Europe (excluding Switzerland) | 55.0 | 57.0 | 60.8 | 71.7 | 79.6 |
| - Americas | 71.7 | 74.2 | 80.2 | 111.7 | 92.1 |
| - Asia / Pacific / Others | 24.1 | 26.3 | 28.0 | 34.1 | 35.3 |
| Investments (expenses) in research and development | -25.1 | -27.3 | -25.1 | -22.7 | -24.3 |
| Operating result (EBIT) | -5.8 | 1.1 | 15.2 | 28.8 | 24.6 |
| - in % of net sales | -3.6 | 0.6 | 8.5 | 12.8 | 11.4 |
| Operating result (EBIT) excl. research and development | 19.3 | 28.4 | 40.3 | 51.5 | 48.9 |
| - in % of net sales | 12.2 | 17.0 | 22.6 | 22.8 | 22.7 |
Other operating income 2025
in CHF million
12.9
Operating result (EBIT) 2025
in CHF million
0.0
Fixed assets & assets built for sale 2025
in CHF million
179.1
Employees (FTE) 2025
31
| Technologycluster & Infrastructure | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
in CHF million | |||||
| Other operating income | 12.9 | 13.3 | 12.6 | 12.7 | 12.0 |
| Operating result (EBIT) | 0.0 | 2.9 | 5.2 | 2.9 | 2.5 |
| Fixed assets & assets built for sale | 179.1 | 144.8 | 122.9 | 127.4 | 106.4 |
Net sales 2025
in CHF million
34.5
Trading operating result 2025
in CHF million / in % of net sales
–8.8 / –25.5%
Result of strategic investments (associated companies) 2025
in CHF million
-2.9
Operating result (EBIT) 2025
in CHF million
–11.7
Organic net sales development 2025
in %
1.7%
Employees (FTE) 2025
154
| Investments & Corporate | 2025 |
| 2024 | 1) | 2023 | 2022 | 2) | 2021 |
|---|---|---|---|---|---|---|---|---|
in CHF million | ||||||||
| Net sales | 34.5 | 49.1 | 117.3 | 86.2 | 68.4 | |||
| Net sales development in % | -29.7 | -58.1 | 36.1 | 26.1 | -9.5 | |||
| - of which foreign currency impact in % | 0.0 | -0.1 | -1.3 | 0.5 | 0.0 | |||
| - of which acquisition impact in % | -31.4 | 3) | -46.1 | 3) | 0.0 | 0.0 | 0.0 | |
| Organic net sales development in % | 1.7 | -11.9 | 37.4 | 25.6 | -9.5 | |||
| Net sales to third parties | 34.5 | 48.4 | 115.5 | 84.1 | 67.7 | |||
| - Switzerland | 34.4 | 36.2 | 45.3 | 41.4 | 32.5 | |||
| - Europe (excluding Switzerland) | 0.1 | 8.4 | 45.3 | 25.5 | 18.3 | |||
| - Americas | 0.0 | 3.3 | 18.4 | 8.4 | 12.8 | |||
| - Asia / Pacific / Others | 0.0 | 0.6 | 6.6 | 8.8 | 4.1 | |||
| Trading operating result | -8.8 | 54.8 | 4) | -4.0 | 82.6 | 5) | -2.1 | |
| - in % of net sales | -25.5 | 111.7 | -3.4 | 95.8 | -3.0 | |||
| Result from strategic investments (associated companies) | -2.9 | 3.1 | 17.0 | 9.9 | 18.9 | |||
| Operating result (EBIT) | -11.7 | 57.9 | 4) | 13.0 | 92.5 | 5) | 16.9 |
1) Contains the pro rata results of the Belimed Life Science Group up to June 7, 2024. |
2) As of January 1, 2022, Belimed Life Science, which is included in the Investments & Corporate reporting segment, took over the service business for Life Science Customers from the Infection Control Business Unit. This impact is included in the organic net sales development. The 2021 sales for this service business amounted to CHF 12.0 million (17.5% of the 2021 sales). |
3) 2025 and 2024 solely in connection with the deconsolidation of the Business Unit Infection Control and the Belimed Life Science Group. |
4) Includes the gain of CHF 66.6 million related to the deconsolidation of the Infection Control Business Unit and the Belimed Life Science Group and their contribution into the newly founded joint venture SteelcoBelimed AG in exchange for a minority stake of 33 % in SteelcoBelimed AG. |
5) Includes the gain of CHF 89.7 million from the contribution of the Schleuniger Group into the Komax Group in exchange for a minority stake of 25% in Komax Holding AG. |